130 related articles for article (PubMed ID: 11532308)
1. Effect of PSC 833 liposomes and Intralipid on the transport of epirubicin in Caco-2 cells and rat intestines.
Lo Y; Liu F; Cherng J
J Control Release; 2001 Sep; 76(1-2):1-10. PubMed ID: 11532308
[TBL] [Abstract][Full Text] [Related]
2. Reversal of multidrug resistance to epirubicin by cyclosporin A in liposomes or intralipid.
Lo YL; Liu FI; Yang JM; Cherng JY
Anticancer Res; 2001; 21(1A):445-50. PubMed ID: 11299776
[TBL] [Abstract][Full Text] [Related]
3. Phospholipids as multidrug resistance modulators of the transport of epirubicin in human intestinal epithelial Caco-2 cell layers and everted gut sacs of rats.
Lo YL
Biochem Pharmacol; 2000 Nov; 60(9):1381-90. PubMed ID: 11008132
[TBL] [Abstract][Full Text] [Related]
4. Relationships between the hydrophilic-lipophilic balance values of pharmaceutical excipients and their multidrug resistance modulating effect in Caco-2 cells and rat intestines.
Lo YL
J Control Release; 2003 Jun; 90(1):37-48. PubMed ID: 12767705
[TBL] [Abstract][Full Text] [Related]
5. Effects of sodium deoxycholate and sodium caprate on the transport of epirubicin in human intestinal epithelial Caco-2 cell layers and everted gut sacs of rats.
Lo YL; Huang JD
Biochem Pharmacol; 2000 Mar; 59(6):665-72. PubMed ID: 10677583
[TBL] [Abstract][Full Text] [Related]
6. Liposomal doxorubicin circumvents PSC 833-free drug interactions, resulting in effective therapy of multidrug-resistant solid tumors.
Krishna R; Mayer LD
Cancer Res; 1997 Dec; 57(23):5246-53. PubMed ID: 9393743
[TBL] [Abstract][Full Text] [Related]
7. Modulation and prevention of multidrug resistance by inhibitors of P-glycoprotein.
Sikic BI; Fisher GA; Lum BL; Halsey J; Beketic-Oreskovic L; Chen G
Cancer Chemother Pharmacol; 1997; 40 Suppl():S13-9. PubMed ID: 9272128
[TBL] [Abstract][Full Text] [Related]
8. Reversing multidrug resistance in Caco-2 by silencing MDR1, MRP1, MRP2, and BCL-2/BCL-xL using liposomal antisense oligonucleotides.
Lo YL; Liu Y
PLoS One; 2014; 9(3):e90180. PubMed ID: 24637737
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of P-glycoprotein-mediated vinblastine transport across HCT-8 intestinal carcinoma monolayers by verapamil, cyclosporine A and SDZ PSC 833 in dependence on extracellular pH.
Zacherl J; Hamilton G; Thalhammer T; Riegler M; Cosentini EP; Ellinger A; Bischof G; Schweitzer M; Teleky B; Koperna T
Cancer Chemother Pharmacol; 1994; 34(2):125-32. PubMed ID: 7910786
[TBL] [Abstract][Full Text] [Related]
10. Comparison of effects of surfactants with other MDR reversing agents on intracellular uptake of epirubicin in Caco-2 cell line.
Lo YL; Hsu CY; Huang JD
Anticancer Res; 1998; 18(4C):3005-9. PubMed ID: 9713500
[TBL] [Abstract][Full Text] [Related]
11. Co-encapsulation of chrysophsin-1 and epirubicin in PEGylated liposomes circumvents multidrug resistance in HeLa cells.
Lo YL; Tu WC
Chem Biol Interact; 2015 Dec; 242():13-23. PubMed ID: 26335193
[TBL] [Abstract][Full Text] [Related]
12. Circumvention of P-glycoprotein-mediated drug resistance in human leukaemic cells by non-immunosuppressive cyclosporin D analogue, SDZ PSC 833.
Jiang XR; Kelsey SM; Wu YL; Newland AC
Br J Haematol; 1995 Jun; 90(2):375-83. PubMed ID: 7794760
[TBL] [Abstract][Full Text] [Related]
13. Effect on cell kill of addition of multidrug resistance modifiers cyclosporin A and PSC 833 to cytotoxic agents in acute myeloid leukaemia.
Grey M; Borg AG; Wood P; Burgess R; Fisher A; Yin JA
Leuk Res; 1997 Sep; 21(9):867-74. PubMed ID: 9393602
[TBL] [Abstract][Full Text] [Related]
14. The Use of a Liposomal Formulation Incorporating an Antimicrobial Peptide from Tilapia as a New Adjuvant to Epirubicin in Human Squamous Cell Carcinoma and Pluripotent Testicular Embryonic Carcinoma Cells.
Lo YL; Lee HP; Tu WC
Int J Mol Sci; 2015 Sep; 16(9):22711-34. PubMed ID: 26393585
[TBL] [Abstract][Full Text] [Related]
15. Modulation of multidrug resistance by SDZ PSC 833 in leukemic and solid-tumor-bearing mouse models.
Watanabe T; Naito M; Oh-hara T; Itoh Y; Cohen D; Tsuruo T
Jpn J Cancer Res; 1996 Feb; 87(2):184-93. PubMed ID: 8609068
[TBL] [Abstract][Full Text] [Related]
16. Overcoming multidrug resistance using liposomal epirubicin and antisense oligonucleotides targeting pump and nonpump resistances in vitro and in vivo.
Lo YL; Liu Y; Tsai JC
Biomed Pharmacother; 2013 May; 67(4):261-7. PubMed ID: 23540284
[TBL] [Abstract][Full Text] [Related]
17. Relevance of p-glycoprotein for the enteral absorption of cyclosporin A: in vitro-in vivo correlation.
Fricker G; Drewe J; Huwyler J; Gutmann H; Beglinger C
Br J Pharmacol; 1996 Aug; 118(7):1841-7. PubMed ID: 8842452
[TBL] [Abstract][Full Text] [Related]
18. The use of liposomal anticancer agents to determine the roles of drug pharmacodistribution and P-glycoprotein (PGP) blockade in overcoming multidrug resistance (MDR).
Krishna R; Mayer LD
Anticancer Res; 1999; 19(4B):2885-91. PubMed ID: 10652569
[TBL] [Abstract][Full Text] [Related]
19. Altered activity of MDR-reversing agents on KB3-1 cells transfected with Gly(185)-->Val human P-glycoprotein.
Watanabe T; Uchiyama N; Roninson IB; Cohen D; Atadja P
Int J Oncol; 2000 Sep; 17(3):579-86. PubMed ID: 10938401
[TBL] [Abstract][Full Text] [Related]
20. Initial pharmacokinetics and bioavailability of PSC 833, a P-glycoprotein antagonist.
Lush RM; Meadows B; Fojo AT; Kalafsky G; Smith HT; Bates S; Figg WD
J Clin Pharmacol; 1997 Feb; 37(2):123-8. PubMed ID: 9055138
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
